×
Wednesday, April 24, 2024

DEADLINE APPROACHING: Berger Montague Advises Charles River Laboratories International, Inc. (CRL) Investors to Inquire About a Securities Fraud Action by July 18, 2023

Last updated Wednesday, July 12, 2023 10:05 ET

Vancouver Canada · V6E 4A6, Canada, 07/12/2023 / SubmitMyPR /

Philadelphia, Pennsylvania--(Newsfile Corp. - July 12, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Charles River Laboratories International, Inc. ("Charles River") (NYSE: CRL) on behalf of those who purchased Charles River securities between May 7, 2020 and February 21, 2023, inclusive (the "Class Period").

Investor Deadline: Investors who purchased or acquired Charles River securities during the Class Period may, no later than July 18, 2023, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected] or (215) 875-3015 or visit: https://investigations.bergermontague.com/charles-river-laboratories-securities-investigation/.

Charles River is a full-service, non-clinical global drug development partner with a mission to create healthier lives. The company has three reporting segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The Discovery and Safety Assessment segment accounts for approximately 60% of Charles River's total revenue and offers, among other things, safety assessment studies required for regulatory submission of therapeutic solutions.

On February 22, 2023, before the market opened, Charles River revealed that it had received a subpoena from the U.S. Department of Justice ("DOJ") relating to an ongoing investigation in conjunction with the U.S. Fish and Wildlife Service ("USFWS") into the supply chain and illegal importation of non-human primates for research. The Company noted that it was voluntarily suspending shipments of primates from Cambodia, which would negatively impact its earnings for the year and would reduce revenue growth by 200 basis points to 400 basis points. Following this news, Charles River's stock price fell $24.51, or 10%, to close at $219.09 per share on February 22, 2023.

The complaint alleges that throughout the Class Period, the defendants failed to disclose to investors that: (1) Charles River had engaged in illegal activity with respect to its importation of non-human primates for research; (2) as a result, Charles River was at a heightened risk of criminal and regulatory investigation by, inter alia, the DOJ; (3) as a result, Charles River would be forced to suspend shipments of primates from Cambodia; and (4) as a result of the foregoing, Defendants' positive statements about Charles River's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., San Diego, San Francisco, Chicago, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/173174

Original Source of the original story >> DEADLINE APPROACHING: Berger Montague Advises Charles River Laboratories International, Inc. (CRL) Investors to Inquire About a Securities Fraud Action by July 18, 2023